{"schemaVersion":"ready-scan.discovery-entity.v3","id":"urn:readyscan:entity:karamata-q141277596","slug":"karamata-q141277596","kind":"entity","entityType":"Organization","canonicalUrl":"https://readyscan.ai/entities/karamata-q141277596","machineUrl":"https://readyscan.ai/discovery/entities/karamata-q141277596.json","llmsUrl":"https://readyscan.ai/entities/karamata-q141277596/llms.txt","name":"KARAMATA","alternateNames":[],"websiteUrl":"https://karamataclinical.com/","category":{"slug":"businesses","name":"Businesses","canonicalUrl":"https://readyscan.ai/directory/businesses"},"description":"KARAMATA: “KARAMATA is an American clinical research services company specializing in hematology and oncology, with clinical research finance and regulatory disclosure services available across therapeutic areas.”","summary":"KARAMATA: “KARAMATA is an American clinical research services company specializing in hematology and oncology, with clinical research finance and regulatory disclosure services available across therapeutic areas.”","localizedDescriptions":[],"claims":[{"id":"content-native-digital-agencies-75cf7cfeeb632825-a-c275b9c792cf4bd34c37","label":"KARAMATA","value":"“KARAMATA is an American clinical research services company specializing in hematology and oncology, with clinical research finance and regulatory disclosure services available across therapeutic areas.”","sourceIds":["source-record"]},{"id":"content-native-digital-agencies-75cf7cfeeb632825-a-eaa3df01a6d4e3fecbdf","label":"01When should therapeutic strategy enter the operating plan?","value":"“Before design assumptions harden; early work should define evidence needs, decision gates, and ownership.”","sourceIds":["source-1003e63c165b448a"]},{"id":"content-native-digital-agencies-75cf7cfeeb632825-a-e3c21708389c31458219","label":"02What inputs are needed to begin?","value":"“Disease setting, phase, modality, protocol concept, available evidence, and open decisions.”","sourceIds":["source-1003e63c165b448a"]},{"id":"content-native-digital-agencies-75cf7cfeeb632825-a-e13f4f3e7c14ea24b92b","label":"03How are biomarkers connected to execution?","value":"“Selection, assay, sampling, endpoint, data, and operational implications are mapped together.”","sourceIds":["source-1003e63c165b448a"]},{"id":"content-native-digital-agencies-75cf7cfeeb632825-a-01ea6ddbbbd2b5a8dca4","label":"04What does KARAMATA own?","value":"“The engagement scope defines analysis, planning, documentation, coordination, and decision support.”","sourceIds":["source-1003e63c165b448a"]},{"id":"content-native-digital-agencies-75cf7cfeeb632825-a-dbe6e48eb6246d5d3b1f","label":"05What remains with the client?","value":"“Program direction, approvals, regulatory and legal judgments, and release authority remain explicit.”","sourceIds":["source-1003e63c165b448a"]},{"id":"content-native-digital-agencies-75cf7cfeeb632825-a-fe743884b9e3a712b674","label":"06How are exceptions handled?","value":"“Open questions, assumptions, disagreements, and unresolved evidence are documented and escalated.”","sourceIds":["source-1003e63c165b448a"]},{"id":"wikidata-p571-0d5ce9d60e159651","label":"Founded","value":"2026-02-03","sourceIds":["source-8be9d24e75cf39cc"]}],"knowledge":{"offerings":[],"answers":[{"id":"content-native-digital-agencies-75cf7cfeeb632825-a-eaa3df01a6d4e3fecbdf","question":"01When should therapeutic strategy enter the operating plan?","answer":"“Before design assumptions harden; early work should define evidence needs, decision gates, and ownership.”","sourceIds":["source-1003e63c165b448a"],"claimIds":["content-native-digital-agencies-75cf7cfeeb632825-a-eaa3df01a6d4e3fecbdf"]},{"id":"content-native-digital-agencies-75cf7cfeeb632825-a-e3c21708389c31458219","question":"02What inputs are needed to begin?","answer":"“Disease setting, phase, modality, protocol concept, available evidence, and open decisions.”","sourceIds":["source-1003e63c165b448a"],"claimIds":["content-native-digital-agencies-75cf7cfeeb632825-a-e3c21708389c31458219"]},{"id":"content-native-digital-agencies-75cf7cfeeb632825-a-e13f4f3e7c14ea24b92b","question":"03How are biomarkers connected to execution?","answer":"“Selection, assay, sampling, endpoint, data, and operational implications are mapped together.”","sourceIds":["source-1003e63c165b448a"],"claimIds":["content-native-digital-agencies-75cf7cfeeb632825-a-e13f4f3e7c14ea24b92b"]},{"id":"content-native-digital-agencies-75cf7cfeeb632825-a-01ea6ddbbbd2b5a8dca4","question":"04What does KARAMATA own?","answer":"“The engagement scope defines analysis, planning, documentation, coordination, and decision support.”","sourceIds":["source-1003e63c165b448a"],"claimIds":["content-native-digital-agencies-75cf7cfeeb632825-a-01ea6ddbbbd2b5a8dca4"]},{"id":"content-native-digital-agencies-75cf7cfeeb632825-a-dbe6e48eb6246d5d3b1f","question":"05What remains with the client?","answer":"“Program direction, approvals, regulatory and legal judgments, and release authority remain explicit.”","sourceIds":["source-1003e63c165b448a"],"claimIds":["content-native-digital-agencies-75cf7cfeeb632825-a-dbe6e48eb6246d5d3b1f"]},{"id":"content-native-digital-agencies-75cf7cfeeb632825-a-fe743884b9e3a712b674","question":"06How are exceptions handled?","answer":"“Open questions, assumptions, disagreements, and unresolved evidence are documented and escalated.”","sourceIds":["source-1003e63c165b448a"],"claimIds":["content-native-digital-agencies-75cf7cfeeb632825-a-fe743884b9e3a712b674"]}],"developments":[]},"sources":[{"id":"source-record","title":"KARAMATA website","publisher":"karamataclinical.com","url":"https://karamataclinical.com/","accessedOn":"2026-10-25","relatedPublicationsUrl":"https://readyscan.ai/sources/source-75cf7cfeeb632825"},{"id":"source-1003e63c165b448a","title":"karamataclinical.com/expertise","publisher":"karamataclinical.com","url":"https://karamataclinical.com/expertise","accessedOn":"2026-10-25","relatedPublicationsUrl":"https://readyscan.ai/sources/source-1003e63c165b448a"},{"id":"source-8be9d24e75cf39cc","title":"wikidata.org/wiki/Special:EntityData/Q141277596.json","publisher":"wikidata.org","url":"https://www.wikidata.org/wiki/Special:EntityData/Q141277596.json?revision=2540073788","accessedOn":"2026-10-25","relatedPublicationsUrl":"https://readyscan.ai/sources/source-8be9d24e75cf39cc"}],"ownership":{"state":"public_sourced_unclaimed","notice":"Public-source record; owner verification is not claimed.","provenance":{"snapshotId":"karamata-q141277596-content-cd61058d0b4743b5-snapshot","sourceId":"ready-scan-subjects","sourceRecordId":"Q141277596","sourceRevisionId":"Q141277596:content:eb6af0706acbc013","sourceContentHash":"fnv1a64:d9841316c5ab6b12","recordRevisionId":"Q141277596:content:eb6af0706acbc013","recordContentHash":"fnv1a64:958f11de4251c3f5","sourceCanonicalUrl":"https://karamataclinical.com/","sourceModifiedAt":"2026-10-25T01:39:45.877Z","observedOn":"2026-10-25","permission":{"basis":"public_information","evidenceUrl":"https://karamataclinical.com/"},"attributionUrl":"https://karamataclinical.com/"}},"datePublished":"2026-10-25","dateModified":"2026-10-25","contentFingerprint":"fnv1a64:607baf47e86e84ec","revision":"fnv1a64:cb50b87d419ae55e","agentProtocol":{"discovery":"https://readyscan.ai/api/v1/ai-search/discovery","evidence":"https://readyscan.ai/api/v1/ai-search/entities/karamata-q141277596/evidence"},"structuredData":{"@context":"https://schema.org","@id":"https://readyscan.ai/entities/karamata-q141277596#entity","name":"KARAMATA","identifier":"urn:readyscan:entity:karamata-q141277596","description":"KARAMATA: “KARAMATA is an American clinical research services company specializing in hematology and oncology, with clinical research finance and regulatory disclosure services available across therapeutic areas.”","url":"https://karamataclinical.com/","mainEntityOfPage":"https://readyscan.ai/entities/karamata-q141277596","datePublished":"2026-10-25","dateModified":"2026-10-25","citation":["https://karamataclinical.com/","https://karamataclinical.com/expertise","https://www.wikidata.org/wiki/Special:EntityData/Q141277596.json?revision=2540073788"],"additionalProperty":[{"@type":"PropertyValue","propertyID":"ownership-state","name":"Ownership state","value":"public_sourced_unclaimed"},{"@type":"PropertyValue","propertyID":"content-fingerprint","name":"Material content fingerprint","value":"fnv1a64:607baf47e86e84ec"},{"@type":"PropertyValue","propertyID":"source-record","name":"Source record","value":"ready-scan-subjects/Q141277596"},{"@type":"PropertyValue","propertyID":"source-revision","name":"Source revision","value":"Q141277596:content:eb6af0706acbc013"},{"@type":"PropertyValue","propertyID":"claim:content-native-digital-agencies-75cf7cfeeb632825-a-c275b9c792cf4bd34c37","name":"KARAMATA","value":"“KARAMATA is an American clinical research services company specializing in hematology and oncology, with clinical research finance and regulatory disclosure services available across therapeutic areas.”"},{"@type":"PropertyValue","propertyID":"claim:content-native-digital-agencies-75cf7cfeeb632825-a-eaa3df01a6d4e3fecbdf","name":"01When should therapeutic strategy enter the operating plan?","value":"“Before design assumptions harden; early work should define evidence needs, decision gates, and ownership.”"},{"@type":"PropertyValue","propertyID":"claim:content-native-digital-agencies-75cf7cfeeb632825-a-e3c21708389c31458219","name":"02What inputs are needed to begin?","value":"“Disease setting, phase, modality, protocol concept, available evidence, and open decisions.”"},{"@type":"PropertyValue","propertyID":"claim:content-native-digital-agencies-75cf7cfeeb632825-a-e13f4f3e7c14ea24b92b","name":"03How are biomarkers connected to execution?","value":"“Selection, assay, sampling, endpoint, data, and operational implications are mapped together.”"},{"@type":"PropertyValue","propertyID":"claim:content-native-digital-agencies-75cf7cfeeb632825-a-01ea6ddbbbd2b5a8dca4","name":"04What does KARAMATA own?","value":"“The engagement scope defines analysis, planning, documentation, coordination, and decision support.”"},{"@type":"PropertyValue","propertyID":"claim:content-native-digital-agencies-75cf7cfeeb632825-a-dbe6e48eb6246d5d3b1f","name":"05What remains with the client?","value":"“Program direction, approvals, regulatory and legal judgments, and release authority remain explicit.”"},{"@type":"PropertyValue","propertyID":"claim:content-native-digital-agencies-75cf7cfeeb632825-a-fe743884b9e3a712b674","name":"06How are exceptions handled?","value":"“Open questions, assumptions, disagreements, and unresolved evidence are documented and escalated.”"},{"@type":"PropertyValue","propertyID":"claim:wikidata-p571-0d5ce9d60e159651","name":"Founded","value":"2026-02-03"}],"@type":"Organization"}}